Oncolytics Biotech (ONCY) Enterprise Value (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Enterprise Value data on file, last reported at -$5.2 million in Q4 2025.

• On a quarterly basis, Enterprise Value rose 57.06% year-over-year to -$5.2 million in Q4 2025; TTM through Dec 2025 was -$5.2 million, a 57.06% increase from a year earlier, with the FY2025 full-year figure at -$5.2 million, up 57.91% from the prior year.
• Enterprise Value for Q4 2025 stood at -$5.2 million, up from -$9.0 million in the prior quarter.
• Over the last five years, Enterprise Value for ONCY reached as high as -$5.2 million in Q4 2025 and fell as low as -$41.3 million in Q2 2021.
• Historically, Enterprise Value has averaged -$21.3 million across 5 years, with a median of -$20.1 million in 2024.
• Across the five-year window, Enterprise Value surged 73.75% in 2022 and tumbled 198.38% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$32.7 million in 2021, then jumped by 73.75% to -$8.6 million in 2022, then plunged by 198.38% to -$25.6 million in 2023, then jumped by 52.76% to -$12.1 million in 2024, then surged by 57.06% to -$5.2 million in 2025.
• Per Business Quant data, the three most recent Enterprise Value figures were -$5.2 million in Q4 2025, -$9.0 million in Q3 2025, and -$10.6 million in Q2 2025.